Ligand Pharmaceuticals Inc (LGND)
71.00
+1.11
(+1.59%)
USD |
NASDAQ |
Apr 24, 16:00
70.90
-0.10
(-0.14%)
After-Hours: 20:00
Ligand Pharmaceuticals Enterprise Value: 1.087B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 1.087B |
| April 23, 2024 | 1.067B |
| April 22, 2024 | 1.043B |
| April 19, 2024 | 1.113B |
| April 18, 2024 | 1.114B |
| April 17, 2024 | 1.226B |
| April 16, 2024 | 1.245B |
| April 15, 2024 | 1.242B |
| April 12, 2024 | 1.270B |
| April 11, 2024 | 1.271B |
| April 10, 2024 | 1.260B |
| April 09, 2024 | 1.273B |
| April 08, 2024 | 1.239B |
| April 05, 2024 | 1.210B |
| April 04, 2024 | 1.210B |
| April 03, 2024 | 1.153B |
| April 02, 2024 | 1.126B |
| April 01, 2024 | 1.133B |
| March 28, 2024 | 1.124B |
| March 27, 2024 | 1.092B |
| March 26, 2024 | 1.045B |
| March 25, 2024 | 1.056B |
| March 22, 2024 | 1.087B |
| March 21, 2024 | 1.121B |
| March 20, 2024 | 1.124B |
| Date | Value |
|---|---|
| March 19, 2024 | 1.108B |
| March 18, 2024 | 1.107B |
| March 15, 2024 | 1.088B |
| March 14, 2024 | 1.103B |
| March 13, 2024 | 1.118B |
| March 12, 2024 | 1.111B |
| March 11, 2024 | 1.109B |
| March 08, 2024 | 1.136B |
| March 07, 2024 | 1.113B |
| March 06, 2024 | 1.117B |
| March 05, 2024 | 1.140B |
| March 04, 2024 | 1.180B |
| March 01, 2024 | 1.223B |
| February 29, 2024 | 1.235B |
| February 28, 2024 | 1.323B |
| February 27, 2024 | 1.409B |
| February 26, 2024 | 1.147B |
| February 23, 2024 | 1.162B |
| February 22, 2024 | 1.121B |
| February 21, 2024 | 1.105B |
| February 20, 2024 | 1.100B |
| February 16, 2024 | 1.123B |
| February 15, 2024 | 1.140B |
| February 14, 2024 | 1.122B |
| February 13, 2024 | 1.076B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
615.03M
Minimum
Mar 16 2020
3.502B
Maximum
Feb 09 2021
1.469B
Average
1.329B
Median
Mar 05 2020
Enterprise Value Benchmarks
| ANI Pharmaceuticals Inc | 1.468B |
| ADMA Biologics Inc | 1.554B |
| Viking Therapeutics Inc | 6.177B |
| Corcept Therapeutics Inc | 1.959B |
| Palatin Technologies Inc | 18.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 18.19M |
| Revenue (Quarterly) | 28.10M |
| Total Expenses (Quarterly) | 31.46M |
| EPS Diluted (Quarterly) | 1.03 |
| Gross Profit Margin (Quarterly) | 94.16% |
| Profit Margin (Quarterly) | 64.72% |
| Earnings Yield | 4.08% |
| Operating Earnings Yield | 0.78% |
| Normalized Earnings Yield | 1.299 |